Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer

N. Eskander, Ramez; W. Sill, Michael; Beffa, Lindsey; G. Moore, Richard; M. Hope, Joanie; Musa, Fernanda; S. Mannel, Robert; S. Shahin, Mark; Cantuaria, Guilherme; Girda, Eugenia; Mathews, Cara; Kavecansky, Juraj; A. Leath, Charles; T. Gien, Lilian; Hinchcliff, Emily; Lele, Shashikant; M. Landrum, Lisa; Backes, Floor; E. O’Cearbhaill, Roisin; Al Baghdadi, Tareq; K. Hill, Emily; H. Thaker, Premal; S. John, Veena; Welch, Stephen; N. Fader, Amanda; A. Powell, Matthew; Aghajanian, Carol

doi:10.1056/nejmoa2302312

Public

Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer

Published in New England Journal of Medicine • Mar 27, 2023

Authors:

Ramez N. Eskander

Michael W. Sill

Lindsey Beffa

Abstract

BACKGROUND: Standard first-line chemotherapy for endometrial cancer is paclitaxel plus carboplatin. The benefit of adding pembrolizumab to chemotherapy remains unclear. METHODS: In this double-blind, placebo-controlled, randomized, phase 3 trial, we assigned 816 patients with measurable disease (sta...

Subject

Medicine

Pembrolizumab

Hazard ratio

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!